CLYM today
$12.25+$0.51 (+4.34%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourStrong Bullish
15 minLeaning Bearish
5 minStrong Bullish
Daily trend turns up above $10.55
Key levels
Resistance$14.53
Resistance$13.09
Support$12.01
Support$10.55
Latest news & SEC filings
AnalystFreedom Capital Markets starts coverage of Climb Bio with bullish rating
AnalystWedbush keeps Outperform rating on Climb Bio, lifts target to $27
AnalystAnalyst Firm Sets $27 Target for Climb Bio
All CLYM news →About Climb Bio
Climb Bio develops therapies for immune-mediated diseases and is still in the clinical testing phase. Its main candidate, budoprutug, is an antibody that depletes B cells carrying the CD19 marker and is being tested in primary membranous nephropathy, immune thrombocytopenia, and lupus. A second candidate, CLYM116, targets APRIL and is aimed at IgA nephropathy and related conditions. The company runs trials in the United States, Australia, and China.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
Climb Bio, Inc. (CLYM)
What Is the Price Target for CLYM?
SEPT Low Target
$18.00
SEPT Mid Target
$25.00
SEPT High Target
$32.00
Analyst Consensus
$25.00
Is CLYM a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CLYM.
Start Free Trial →Is CLYM Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$20.80
12
Moat Score
NONE
1/9
Piotroski Score
49.2
Altman Z-Score
What Is Smart Money Doing with CLYM?
Insider Signal
SELLING
1 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | director 10% owner | Buy | 10,000 | $35K | Sep 28, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | director 10% owner | Buy | 40,000 | $52K | Sep 28, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CLYM Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
42.48%
FCF Growth YoY
-250.5%
Revenue Trend
UNKNOWN
Dark Pool Trades for CLYM
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CLYM, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:05:01 | $12.25 | 300,000 | $$3.7M | MIDPOINT |
| 21:00:31 | $12.25 | 4,004 | $$49K | MIDPOINT |
| 21:00:29 | $12.25 | 1,068 | $$13K | MIDPOINT |
| 21:00:00 | $12.25 | 2,200 | $$27K | MIDPOINT |
| 20:09:47 | $12.28 | 1,000 | $$12K | SELL |
5 dark pool trades shown · $$3.8M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Climb Bio, Inc. (CLYM) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CLYM — frequently asked questions
What is CLYM stock price today?
Climb Bio, Inc. (CLYM) is at $12.25, up 4.34% (+$0.51) at the Nov 11, 2026 close.
Why is CLYM stock moving today?
Latest CLYM news — Nov 11, 2026: Freedom Capital Markets starts coverage of Climb Bio with bullish rating · Nov 6, 2026: Wedbush keeps Outperform rating on Climb Bio, lifts target to $27
Why did CLYM stock move on Nov 5, 2026?
Climb Bio reported Q3 2026 earnings with a loss of $0.18 per share, beating the $(0.20) consensus estimate, though the stock closed flat at $8.87 after trading between $9.20 and $8.48 on volume of 1,405,506 shares. The company also filed an automatic shelf registration (Form S-3ASR) for future offerings, introducing potential dilution risk that may weigh on sentiment.
What is the CLYM price target?
The average analyst price target for CLYM is $25.00, ranging from $18 to $32, based on 10 analysts.
What do analysts rate CLYM?
Analyst ratings for CLYM: 0 Buy, 23 Hold, 0 Sell — consensus Hold.
Did CLYM beat earnings?
CLYM last reported on Nov 5, 2026: EPS -$0.18 vs -$0.20 expected — a beat of 10.0%.
Does CLYM pay a dividend?
CLYM does not currently pay a dividend.
What are CLYM support and resistance levels?
Support: $12.01, $10.55, $9.61. Resistance: $13.09, $14.53, $16.17.
What are insiders doing with CLYM?
Insider activity: SELLING, 1 buys and 4 sells in the last 90 days.
What is the latest news on CLYM?
Nov 11, 2026: Freedom Capital Markets starts coverage of Climb Bio with bullish rating · Nov 6, 2026: Wedbush keeps Outperform rating on Climb Bio, lifts target to $27 · Nov 5, 2026: Analyst Firm Sets $27 Target for Climb Bio